Description
FREE — Live Online
11:00 am — 12:00 pm (PT) Pacific Time Zone
This is a 1-hour free class that covers how to use the Biphasic Mode in NeuroField64™ for Vagus Nerve Stimulation.
Learn how to utilize a newly designed electrode and nine (9) new protocols and clinical uses for VNS Therapy.
The vagus nerve is a cranial nerve that runs from the brainstem to various organs in the body.
Vagus nerve stimulation (VNS) is a medical procedure that involves the delivery of electrical impulses to the vagus nerve utilizing a Neurofield™ stimulation device.
Some potential benefits of vagus nerve stimulation include:
- Epilepsy management: VNS has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for people with epilepsy who are not responsive to medications or are unable to undergo surgery. VNS can help reduce the frequency and severity of seizures in some individuals.
- Depression treatment: VNS has been studied as a potential treatment for chronic or treatment-resistant depression. The electrical impulses delivered to the vagus nerve may help regulate mood by modulating brain activity. VNS for depression is typically used in conjunction with other therapies and medications.
- Cluster headache relief: Cluster headaches are severe and recurring headaches that can be debilitating for those who experience them. Vagus nerve stimulation has shown promise in providing relief for some individuals with chronic cluster headaches.
- Potential for other neurological conditions: Vagus nerve stimulation is being investigated as a potential therapy for other neurological conditions, including post-traumatic stress disorder (PTSD), Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury.
Current research on vagus nerve stimulation identifies it as a potential treatment for a variety of conditions and is looking at the potential benefits of VNS therapy for rheumatoid arthritis, inflammatory bowel disease, bipolar disorder, obesity and Alzheimer’s disease. While research is ongoing, the early results are encouraging.
